Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hepatic Drug Excretion: Influencing Factors01:16

Hepatic Drug Excretion: Influencing Factors

132
The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
132
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

92
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
92
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

559
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
559
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

667
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
667

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

C5b-9 Deposition in Renal Transplant Biopsies Associates With Prolonged Delayed Graft Function in Kidneys Donated After Circulatory Death.

Transplantation·2026
Same author

Urinary NGAL Outperforms <sup>99m</sup>Tc-MAG3 Renography in Predicting DCD Kidney Graft Function.

Transplant international : official journal of the European Society for Organ Transplantation·2025
Same author

Belgian Consensus Guidelines Within Eurotransplant on Imlifidase-enabled Deceased Donor Kidney Transplantation in Highly Sensitized Patients.

Transplantation·2025
Same author

Predicting Kidney Outcomes in Autosomal Dominant Polycystic Kidney Disease: A Comprehensive Biomarker Analysis.

Clinical journal of the American Society of Nephrology : CJASN·2025
Same author

Prospective Study on Individualized Dose Adjustment of Tolvaptan Based on Urinary Osmolality in Patients With ADPKD.

Kidney international reports·2025
Same author

Allogeneic mesenchymal stromal cell therapy in kidney transplantation: should repeated human leukocyte antigen mismatches be avoided?

Frontiers in genetics·2024

Related Experiment Video

Updated: Jul 8, 2025

Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis
08:56

Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis

Published on: February 10, 2015

52.3K

Serum bile acids associate with liver volume in polycystic liver disease and decrease upon treatment with lanreotide.

Shosha E I Dekker1, Jörgen Bierau2, Martin Giera3

  • 1Department of Nephrology, Leiden University Medical Center, Leiden, the Netherlands.

European Journal of Clinical Investigation
|December 10, 2023
PubMed
Summary

In autosomal dominant polycystic kidney disease (ADPKD) with polycystic liver disease (PLD), serum bile acids correlate with liver size. Lanreotide treatment reduced bile acids, but not liver volume, in these patients.

Keywords:
ADPKDPLDbile acidbiomarker

More Related Videos

A Silver Nanoparticle Method for Ameliorating Biliary Atresia Syndrome in Mice
07:48

A Silver Nanoparticle Method for Ameliorating Biliary Atresia Syndrome in Mice

Published on: October 13, 2018

7.7K
A Mouse Model of Chronic Liver Fibrosis for the Study of Biliary Atresia
09:12

A Mouse Model of Chronic Liver Fibrosis for the Study of Biliary Atresia

Published on: February 3, 2023

2.5K

Related Experiment Videos

Last Updated: Jul 8, 2025

Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis
08:56

Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis

Published on: February 10, 2015

52.3K
A Silver Nanoparticle Method for Ameliorating Biliary Atresia Syndrome in Mice
07:48

A Silver Nanoparticle Method for Ameliorating Biliary Atresia Syndrome in Mice

Published on: October 13, 2018

7.7K
A Mouse Model of Chronic Liver Fibrosis for the Study of Biliary Atresia
09:12

A Mouse Model of Chronic Liver Fibrosis for the Study of Biliary Atresia

Published on: February 3, 2023

2.5K

Area of Science:

  • Hepatology
  • Nephrology
  • Biochemistry

Background:

  • Polycystic liver disease (PLD) is a frequent complication of autosomal dominant polycystic kidney disease (ADPKD).
  • Bile acids are implicated in the pathogenesis of PLD.
  • This study investigates bile acid profiles in ADPKD patients with and without PLD.

Purpose of the Study:

  • To determine if serum bile acid levels are elevated in ADPKD patients with PLD.
  • To assess the effect of lanreotide on bile acid levels in PLD.
  • To explore the role of urinary bile acid excretion in renal disease progression in PLD.

Main Methods:

  • Quantification of serum and urine bile acids using liquid chromatography-mass spectrometry.
  • Comparison of 105 PLD ADPKD patients with 52 non-PLD ADPKD controls.
  • Analysis of samples at baseline and after 120 weeks of lanreotide or standard care.

Main Results:

  • Higher baseline serum levels of conjugated bile acids were observed in patients with larger livers.
  • Lanreotide treatment led to a decrease in multiple serum bile acids in PLD patients.
  • No significant changes in urine bile acid levels or correlation with renal disease progression were found.

Conclusions:

  • Serum bile acid levels in ADPKD patients with PLD are associated with liver volume.
  • Lanreotide effectively reduced serum bile acid levels, independent of liver volume changes.
  • Urinary bile acid excretion does not appear to contribute to renal disease progression in this cohort.